NZ759509B2 - Composition, system and method for treating skin - Google Patents
Composition, system and method for treating skin Download PDFInfo
- Publication number
- NZ759509B2 NZ759509B2 NZ759509A NZ75950914A NZ759509B2 NZ 759509 B2 NZ759509 B2 NZ 759509B2 NZ 759509 A NZ759509 A NZ 759509A NZ 75950914 A NZ75950914 A NZ 75950914A NZ 759509 B2 NZ759509 B2 NZ 759509B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- honey
- dressing
- acid
- wound
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 204
- 210000003491 Skin Anatomy 0.000 title abstract description 49
- 235000012907 honey Nutrition 0.000 claims abstract description 157
- 239000011780 sodium chloride Substances 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 53
- 150000007524 organic acids Chemical class 0.000 claims abstract description 30
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 22
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 19
- 235000005985 organic acids Nutrition 0.000 claims abstract description 15
- 230000000699 topical Effects 0.000 claims abstract description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 129
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 66
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 64
- 240000003553 Leptospermum scoparium Species 0.000 claims description 50
- 235000016887 Leptospermum scoparium Nutrition 0.000 claims description 46
- 239000002253 acid Substances 0.000 claims description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 29
- 229960005070 ascorbic acid Drugs 0.000 claims description 29
- 235000010323 ascorbic acid Nutrition 0.000 claims description 29
- 239000011668 ascorbic acid Substances 0.000 claims description 29
- 239000004365 Protease Substances 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 17
- 229940088598 Enzyme Drugs 0.000 claims description 16
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 16
- 229940093915 Gynecological Organic acids Drugs 0.000 claims description 14
- 108090000350 Actinidain Proteins 0.000 claims description 13
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- 239000011736 potassium bicarbonate Substances 0.000 claims description 12
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 12
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 12
- 229940055729 Papain Drugs 0.000 claims description 11
- 108090000526 Papain Proteins 0.000 claims description 11
- 235000019834 papain Nutrition 0.000 claims description 11
- 230000002797 proteolythic Effects 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 235000012208 gluconic acid Nutrition 0.000 claims description 9
- 230000002335 preservative Effects 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 9
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000174 gluconic acid Substances 0.000 claims description 8
- 229950006191 gluconic acid Drugs 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 claims description 7
- -1 ain Proteins 0.000 claims description 7
- 239000001099 ammonium carbonate Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 229940094025 potassium bicarbonate Drugs 0.000 claims description 7
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 229960004275 glycolic acid Drugs 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 229940099690 malic acid Drugs 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- 229960002510 mandelic acid Drugs 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 229960000583 Acetic Acid Drugs 0.000 claims description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 4
- 108090000200 Cucumisin Proteins 0.000 claims description 4
- 108090000270 Ficain Proteins 0.000 claims description 4
- 229940069338 Potassium Sorbate Drugs 0.000 claims description 4
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 claims description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N Thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 4
- 239000005844 Thymol Substances 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- 229940067596 butylparaben Drugs 0.000 claims description 4
- 235000019836 ficin Nutrition 0.000 claims description 4
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 239000001184 potassium carbonate Substances 0.000 claims description 4
- 239000004302 potassium sorbate Substances 0.000 claims description 4
- 235000010241 potassium sorbate Nutrition 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 239000001187 sodium carbonate Substances 0.000 claims description 4
- 229930007823 thymol Natural products 0.000 claims description 4
- 229960000790 thymol Drugs 0.000 claims description 4
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 claims description 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 3
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 3
- 229960003885 Sodium Benzoate Drugs 0.000 claims description 3
- 229960005137 Succinic Acid Drugs 0.000 claims description 3
- 125000005587 carbonate group Chemical group 0.000 claims description 3
- 229940093424 polyaminopropyl biguanide Drugs 0.000 claims description 3
- 239000001384 succinic acid Substances 0.000 claims description 3
- 101700058606 K2CO Proteins 0.000 claims description 2
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 2
- 229960002798 cetrimide Drugs 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- GLFDLEXFOHUASB-UHFFFAOYSA-N trimethyl(tetradecyl)azanium Chemical compound CCCCCCCCCCCCCC[N+](C)(C)C GLFDLEXFOHUASB-UHFFFAOYSA-N 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract description 52
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract description 45
- 230000029663 wound healing Effects 0.000 abstract description 17
- 239000002562 thickening agent Substances 0.000 abstract description 10
- 200000000019 wound Diseases 0.000 description 164
- 206010052428 Wound Diseases 0.000 description 152
- 210000001519 tissues Anatomy 0.000 description 56
- 235000002639 sodium chloride Nutrition 0.000 description 54
- 239000001569 carbon dioxide Substances 0.000 description 44
- 239000010410 layer Substances 0.000 description 36
- 238000009472 formulation Methods 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 230000001338 necrotic Effects 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- 210000002615 Epidermis Anatomy 0.000 description 22
- 239000002674 ointment Substances 0.000 description 19
- 238000001804 debridement Methods 0.000 description 18
- 206010040844 Skin exfoliation Diseases 0.000 description 16
- 230000003204 osmotic Effects 0.000 description 16
- AIJULSRZWUXGPQ-UHFFFAOYSA-N pyruvic aldehyde Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 230000035876 healing Effects 0.000 description 15
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 14
- 108091005771 Peptidases Proteins 0.000 description 14
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 14
- 238000004299 exfoliation Methods 0.000 description 14
- 102000035443 Peptidases Human genes 0.000 description 13
- 230000000845 anti-microbial Effects 0.000 description 12
- 239000003085 diluting agent Substances 0.000 description 12
- 239000006260 foam Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 11
- 210000004927 Skin cells Anatomy 0.000 description 10
- 230000001684 chronic Effects 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 208000006123 Myiasis Diseases 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 9
- 230000002255 enzymatic Effects 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 241000195940 Bryophyta Species 0.000 description 8
- 210000000416 Exudates and Transudates Anatomy 0.000 description 8
- 230000002378 acidificating Effects 0.000 description 8
- 230000002358 autolytic Effects 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 235000011929 mousse Nutrition 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 206010000496 Acne Diseases 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 7
- 210000004207 Dermis Anatomy 0.000 description 7
- 241000283073 Equus caballus Species 0.000 description 7
- 206010068760 Ulcers Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 230000037075 skin appearance Effects 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 230000036269 ulceration Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 241000283074 Equus asinus Species 0.000 description 6
- 241000257303 Hymenoptera Species 0.000 description 6
- 229960000448 Lactic acid Drugs 0.000 description 6
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 6
- 208000006641 Skin Disease Diseases 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 229960004106 citric acid Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001264 neutralization Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 240000001101 Actinidia deliciosa Species 0.000 description 5
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 5
- 206010021197 Ichthyosis Diseases 0.000 description 5
- 206010021198 Ichthyosis Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000002262 irrigation Effects 0.000 description 5
- 238000003973 irrigation Methods 0.000 description 5
- 201000004681 psoriasis Diseases 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 102000020504 Collagenase family Human genes 0.000 description 4
- 108060005980 Collagenase family Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 210000000981 Epithelium Anatomy 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 210000001126 Granulation Tissue Anatomy 0.000 description 4
- 240000004119 Melissa officinalis Species 0.000 description 4
- 235000010654 Melissa officinalis Nutrition 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 229940115037 Santyl Drugs 0.000 description 4
- 230000000844 anti-bacterial Effects 0.000 description 4
- 230000003110 anti-inflammatory Effects 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000865 liniment Substances 0.000 description 4
- 230000000813 microbial Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 235000009434 Actinidia chinensis Nutrition 0.000 description 3
- 210000003423 Ankle Anatomy 0.000 description 3
- 240000006432 Carica papaya Species 0.000 description 3
- 235000009467 Carica papaya Nutrition 0.000 description 3
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 3
- 229940108066 Coal Tar Drugs 0.000 description 3
- 210000002808 Connective Tissue Anatomy 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 229940113601 Irrigation Solution Drugs 0.000 description 3
- 229940112580 Kovia Drugs 0.000 description 3
- 241001514662 Leptospermum Species 0.000 description 3
- 210000000088 Lip Anatomy 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- 229940087119 SCOPARIUM Drugs 0.000 description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 150000001277 beta hydroxy acids Chemical class 0.000 description 3
- 235000002354 carica papaya Nutrition 0.000 description 3
- 230000003822 cell turnover Effects 0.000 description 3
- 239000011280 coal tar Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 230000001965 increased Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003020 moisturizing Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001737 promoting Effects 0.000 description 3
- 239000002964 rayon Substances 0.000 description 3
- 238000007389 shave biopsy Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2S,3R,4S,5S,6R)-2-[(2R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 229940061720 Alpha Hydroxy Acids Drugs 0.000 description 2
- 240000005415 Anogeissus latifolia Species 0.000 description 2
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 2
- 229960001334 Corticosteroids Drugs 0.000 description 2
- 206010049796 Excoriation Diseases 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000001922 Gum ghatti Substances 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023347 Keratoacanthoma Diseases 0.000 description 2
- 210000003127 Knee Anatomy 0.000 description 2
- 210000002414 Leg Anatomy 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000008742 Seborrheic Dermatitis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 230000002009 allergen Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 150000005323 carbonate salts Chemical class 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000009488 encapsulation (pharmaceutical) Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019314 gum ghatti Nutrition 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 239000007934 lip balm Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000009581 negative-pressure wound therapy Methods 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000000541 pulsatile Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 206010059394 Acanthoma Diseases 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 229940064804 Betadine Drugs 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L Calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229940113118 Carrageenan Drugs 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 240000003624 Cymbopogon nardus Species 0.000 description 1
- 235000018791 Cymbopogon nardus Nutrition 0.000 description 1
- 108060002187 Def1 Proteins 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 210000003722 Extracellular Fluid Anatomy 0.000 description 1
- 210000000245 Forearm Anatomy 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- 241000557622 Garrulus glandarius Species 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229940015043 Glyoxal Drugs 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 210000003780 Hair Follicle Anatomy 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000002473 Lacerations Diseases 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- 210000001640 Nerve Endings Anatomy 0.000 description 1
- XRJSANGRPFMDJB-ABICQQBESA-M OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO.C([O-])(O)=O.[Na+] Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO.C([O-])(O)=O.[Na+] XRJSANGRPFMDJB-ABICQQBESA-M 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 229940100686 Otic Ointment Drugs 0.000 description 1
- 108009000578 Oxidative Stress Proteins 0.000 description 1
- 229940062900 Papain / Urea Drugs 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 210000002374 Sebum Anatomy 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040943 Skin ulcer Diseases 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 210000001562 Sternum Anatomy 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 102100007953 TES Human genes 0.000 description 1
- 101700059393 TES Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000009056 Telangiectasis Diseases 0.000 description 1
- 101710038191 Testin Proteins 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 229960004319 Trichloroacetic Acid Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000001364 Upper Extremity Anatomy 0.000 description 1
- 206010046736 Urticarias Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 238000005296 abrasive Methods 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002421 anti-septic Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 230000001815 facial Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940055350 kiwi fruit extract Drugs 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002365 multiple layer Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 101710004799 sm-amp-x Proteins 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 231100001005 telangiectasia Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Abstract
topical dressing for wound healing and/or skin treatment comprising a first and second layer of honey and a carbonate and/or bicarbonate salt. The salt is preferably capable of releasing CO2. The composition may optionally comprise thickeners and/or organic acids.
Description
COMPOSITION, SYSTEM AND METHOD FOR TREATING SKIN
CROSS REFERENCE TO PRIOR APPLICATIONS
The present ion claims priority to US Application Number 61/908,611, filed
on November 25, 2014. This application is a divisional of New Zealand patent application
721272, which is the national phase entry in New Zealand of PCT international application
, filed 25 er 2014 and published as . This
application claims the priority of United States patent application US 61/908,611, filed 25
November 2013. The entire contents of each of these applications are incorporated herein
by reference.
FIELD OF THE INVENTION
The present invention s to a topical compositions, s and s for
treating skin. In ular, the invention s to the treatment of wounds and skin
disorders and to cosmetic skin treatment. More particularly, the invention relates to topical
compositions and use of such compositions for promotion of wound healing, and removal of
non-viable body tissue, including removal of ic tissue from wound sites, and superficial
exfoliation of the epidermis for cosmetic improvement of skin appearance.
OUND OF THE INVENTION
Removal of non-viable body tissue is necessary or desirable for a number of
reasons. Necrotic or non-viable tissue can develop within wound sites, including ulcerations
in skin tissue, which may be due to chronic pressure and vascular insufficiency, and wounds
due to physical trauma, burns cal or thermal), and sites of infection. Necrotic tissue
inhibits the normal progression of healing by physically and mically obstructing the
cascade of healing events in a wound site, and commonly harbors pathogens and their
toxins. Removal of necrotic or able skin tissue is a key step in healing such wounds.
When healing medical devices such as Negative Pressure Wound Treatment (“NPWT”) are
ted, it is important to thoroughly debride the wound of ic tissue and ic tissue
prior to using NPWT. This process is referred to as debridement. Debriding of the necrotic
tissue is a first priority in healing the wound and is commonly accomplished by one or more
of the following s: (1) surgical debridement; (2) mechanical debridement; (3)
enzymatic debridement; and (4) autolytic debridement. Surgical debridement and
mechanical debridement, while effective, are often somewhat non-specific and can result in
excessive tissue removal and pain to the patient.
Autolytic debridement involves the use of the body’s own proteolytic enzymes
(proteases) and moisture to rehydrate and digest necrotic tissue. It is typically only used in
cases where the amount of necrotic tissue is relatively small and the slow rate of selfdebridement
is acceptable.
WO 74159
Enzymatic debridement, using proteolytic enzymes such as pepsin or
papain/urea, is highly selective for non-viable tissue only. Examples of known enzymatic
debridement methods and compositions e those taught in US. Pat. No. 6,548,556 and
US Patent Application Publication No. 2009/0010910, as well as commercially known
itions such as Accuzyme®. Although enzymatic ement compositions and
methods are known, there are a number of cks and disadvantages to these
compositions.
Adverse or harmful reactions have been reported in patients using topical
enzymatic debriding compositions comprising papain as the active ingredient, including
hypersensitivity reactions leading to nsion (low blood pressure) and tachycardia (rapid
heart rate). There is also a problem with possible allergic reactions. Papain is derived from
papaya, and debriding compositions based on papain may also contain residual extracts
from papaya. In addition, patients who are allergic to latex may exhibit cross-reactivity with
papaya extracts. An alternative to papain is , a digestive enzyme. However, pepsin is
most active in acidic environments (e.g. pH 2—3) such as the stomach, and is relatively
inactive at pH 6.5 and higher. As a result, pepsin has very limited activity in the more neutral
pH found in other body tissues such as skin and it is not very effective in ing wound
sites. In addition, commercially ble pepsin is lly ed from pig stomach, and
is therefore not acceptable to some patients.
Another issue with topically applied enzymatic compositions is the ability of the
composition to ively coat and penetrate the wound site, and r the enzyme to the
entirety of the wound site. In practice, this can be difficult, particularly if the wound site
penetrates deeply into the body or encompasses multiple layers of different body tissues.
Removal of dead skin cells from the outermost layer (the stratum corneum) of the
epidermis is desirable in certain cosmetic applications. Skin tissue is composed of two
layers, the dermis and the epidermis. The dermis contains hair follicles, nerve endings,
blood vessels, and oil and sweat . The epidermis is the outermost layer and unlike
the , it does not contain blood vessels. The epidermis is composed of a number of
different layers and within the innermost (basal) layers of the epidermis are actively dividing
skin cells known as keratinocytes. With each round of cell division, a generation of cells is
pushed to the next level upwards, until they finally reach the outermost layer of the
epidermis, the stratum corneum. The stratum corneum is composed of a thin layer of
flattened, dead skin cells filled with keratin, and bound together by lipids. The outermost
layer of dead skin cells ofthe stratum corneum sheds off lly, and is continually
replaced by newer layers below. On average, it takes about 28 days for a newly divided
daughter cell to migrate from the basal layer of the epidermis to the outermost layer ofthe
stratum corneum, where it can be shed off; this process is known as cell turnover. However,
the rate of cell turnover can be affected by a number of factors, including hormonal
fluctuations, increasing age, poor health and the local environment (e.g. dry weather). A
build-up of dead skin cells in the outermost layer of skin can cause the skin to appear dull,
dry and ashy. In addition, a build-up of dead skin cells and sebum may plug pores, providing
an ideal site for bacterial infection, which then leads to acne breakouts. icial
exfoliation of the ost layer of skin to remove dead skin cells is thus highly useful for
cosmetically improving skin appearance, and it is also useful for overcoming active acne and
preventing future acne breakouts.
ation of skin tissue can be carried out by ical means or by chemical
means. es of mechanical methods of exfoliation include hand-held tools such as
scrubbing brushes, cloths and sponges, as well as cleansing compositions containing small
beads or granules that act as a gentle abrasive when applied to the skin. However, there
are risks associated with mechanical methods of exfoliation: users may scrub too hard or too
often, and cause damage to the skin. This may result in irritation or drying out of the skin,
which can lead to further problems with the skin.
The most common examples of chemical-based methods of cosmetic exfoliation
include organic acids and retinoids. Weak organic acids, including beta hydroxy acids (e.g.
salicylic acid) and alpha hydroxy acids, work as keratolytic agents, loosening and softening
the outermost layer of the epidermis and thus helping to slough off dead skin cells. Alpha
hydroxy acids, mes referred to as fruit acids, include glycolic acid, lactic acid, citric
acid, mandelic acid and malic acid. Low concentrations of alpha and/or beta hydroxy acids
are available in a y of over-the-counter (OTC) cosmetic products, such as masks,
creams, cleansers, lotions and toners. Application of such acids can cause ng,
redness and irritation, particularly those duals with sensitive skin. Stronger organic
acids, such as phenol and trichloroacetic acid, and higher trations of glycolic acid
(e.g. >10%), penetrate the skin more deeply and can cause chemical burns. As such, these
acids are not available for over-the-counter use and may only be applied by enced
medical professionals. Retinoids are a class of chemical compounds that trigger an se
in the rate of cell turnover. The use of retinoids is not without risk: there are numerous side
effects associated with retinoid use, e sun sensitivity, redness, irritation, and peeling,
flaking skin. A number of retinoid compounds are only available through prescription by a
doctor. As well, retinoids, particularly oral forms, are contraindicated during suspected or
confirmed pregnancy, due to the known association of ids with defects in fetal
development. In on to the above, benzoyl peroxide is commonly used for acne
treatment, as it is both antimicrobial and an exfoliant. However, it often causes skin irritation
and dryness.
Exfoliation of the epidermis with concomitant moisturization is necessary to
manage certain chronic skin conditions such as ichthyosis, psoriasis, seborrheic dermatitis
and eczema. Current treatments for these skin conditions typically include corticosteroids,
coal tar, occlusive ointments and . In certain cases of icthyosis and psoriasis,
retinoids may be prescribed. However, coal tar is often a treatment of last resort, due to the
unpleasant smell and the unknown risks of long-term, low level exposure to potential
carcinogens found in coal tar. Corticosteroids cannot be used for long periods of time, as it
can cause permanent thinning of the skin and telangiectasia.
Honey has historically been used to treat a wide variety of medical concerns,
ing , gastrointestinal disorders, allergies and infections ofthe upper atory
tract. It is known to promote the g of wounds as it provides numerous beneficial
effects, including being anti-inflammatory, antioxidant, antimicrobial and anti-bacterial.
Honey is composed primarily of sugars, mainly fructose and glucose. Most types
of honey are acidic due to the presence of naturally occurring organic acids, and have an
e pH of around 3.9, but can range anywhere from pH 3.2 to 6.1. The water content in
honey is very low, with an e water activity (aw) of 0.6; the water that is t within
honey is bound to the sugar les that make up the bulk of honey, thus making honey
inhospitable to microbial growth. The antimicrobial effect of honey is mainly attributed to the
following factors: its low water content, en peroxide (H202), methylglyoxal, the
antimicrobial peptide bee defensin-1, and its acidic pH.
Honey tates wound healing through its strong osmotic action on body tissue:
as honey contains very little moisture (i.e. has a low water activity), it draws wound exudate
by osmosis from the surrounding tissue. By drawing exudate out ofthe wound site, there is
a constant supply of proteases brought to the wound site, particularly at the ace
between necrotic tissue and viable tissue. As a result, autolytic debridement or ghing
of non-viable body tissue can be significantly enhanced with the use of honey as a wound
dressing. In addition, the tion of wound exudate by honey inhibits zation of the
wound site with microbial growth.
Honey also es wound healing by inhibiting microbial growth within the
wound site, and inhibiting oxidative reactions that cause oxidative stress and inflammation.
In most types of honey, the acidic pH, low water content and enzymatic production of
hydrogen peroxide are the main factors contributing to the antimicrobial activity. However,
for any given type of honey, the s contributing to the antimicrobial activity and the
overall level of antimicrobial activity are variable and highly dependent on the plant species
that the honey bees originally fed upon. Honey derived from bees that have fed exclusively
on Leptospermum scoparium, commonly ed to as Manuka honey, as well as honey
derived from bees that have fed on other s of permum species, is known to
have exceptional anti-microbial effect [1]. Manuka honey, as produced from Leptospermum
species and particularly Leptospermum scoparium, contains significantly higher
concentrations of methylglyoxal compared to other types of honey. The high concentration
of methylglyoxal in Manuka honey is believed to be a major contributing factorto the
ed antimicrobial effect [2]. trations of methylglyoxal in Manuka honey can
vary widely, dependent on the bees and the cultivar(s) of Leptospermum species that have
been fed upon; however, a minimum methylglyoxal concentration of around 150 mg/kg is
believed to be directly responsible for the observed antimicrobial effect [3]. The antimicrobial
effect due to glyoxal in Manuka honey is a non-peroxide effect that is sometimes also
referred to as the “Unique Manuka Factor” (“UMF”), a commercial rating scale that compares
observed antimicrobial activity to solutions of phenol in water (e.g. a UMF of 10 is equivalent
to the crobial effect of 10% v/v phenol in water).
Although honey has numerous beneficial effects on wound treatment, it is
lly in the form of a flowable liquid and can be difficult to keep in place, particularly when
treating chronic wounds that may require long-term care. Specialized dressings may be
required. For e, US. Patent No. 7,714,183 discloses a wound dressing impregnated
with honey, as a means of keeping honey secure over the wound site. r, such
dressings may actually inhibit wound healing by slowing down collagen deposition [4]. Also,
as honey is typically acidic, the application of honey to a wound site may cause pain or
discomfort to the patient.
There is evidence that carbon dioxide gas is beneficial for treating wound sites
and promoting wound healing [5]. This is believed to be due to the Bohr effect, wherein
2014/051124
hemoglobin’s binding affinity to oxygen is inversely related to local acidity and carbon dioxide
concentration. With an increase in local carbon dioxide concentration, the g affinity of
obin decreases. In addition, the body reacts by increasing blood flow to areas where
local carbon dioxide concentration is increased. This may be observed as an increase in
microcirculation of blood flow surrounding the wound area: this increase in circulation
provides greater local oxygen availability and nutrient flow to the wound site, while also
helping to removing wastes from the wound site. A carbon dioxide-enriched environment
also minimizes the possibility of infection by aerobic bacteria. At the same time, there is no
ty or major side effects to the patient to applying carbon e. However, a
disadvantage of carbon dioxide therapy is the need for specialized equipment in orderto
create a localized environment nding the wound site that can be filled with a sufficient
concentration of carbon dioxide to e an effect. This es a source of carbon
dioxide (usually in the form of a pressurized gas cylinder) and a method of delivering carbon
dioxide to form a localized environment around the wound site, which may in turn require
tubing and a syringe to inject carbon dioxide into the wound site and a physical method to
enclose the wound site, e.g. adhesive dressings. As a result, carbon dioxide therapy is not a
method that can be readily carried out without specialized equipment, and often requires the
assistance of a skilled practitioner. An alternative, however, is provided in US
2006/0150988, which describes a cosmetic treatment method wherein carbon dioxide is
ermally red using a polymer solution.
There exists a need for s and agents for removing non-viable or necrotic
tissue from wound sites that overcomes at least one of the deficiencies known in the art.
There also exists a need for compositions for exfoliation of the skin and/or to improve skin
appearance, which overcomes at least one of the deficiencies known in the art.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides compositions that may be used as
desloughing agents, debriding agents, wound treatment agents, veterinary wound care
agents, c skin disorder treatment , cosmetic skin exfoliants or any combination
In one aspect, the invention provides a topical composition comprising:
- honey; and,
- a pharmaceutically acceptable carbonate (CO3-2) and/or bicarbonate
(HCO3-1) salt;
for use as a desloughing agent, a debriding agent, a wound treatment agent,
a veterinary wound care agent, a chronic skin disorder treatment agent, a cosmetic skin
exfoliant or any combination thereof.
In accordance with an aspect of the present invention, there is provided a
ition sing:
- honey;
- a pharmaceutically acceptable salt of carbonate (CO3-2) or bicarbonate
(HCO3-1), that is capable of reacting with an acid or an acidic solution to form carbon e;
wherein the pH of said composition is about 7.0 to 7.4.
The compositions described herein may be used as a desloughing agent, a
debriding agent, a wound treatment agent, a veterinary wound care agent, a chronic skin
disorder treatment agent, and a cosmetic skin exfoliant.
In one embodiment of the present invention, the composition ses
- honey;
- about 2.5 to 20% w/w, preferably about 7.5 to 12.5% w/w, sodium
bicarbonate;
- about 0.2 to 6% w/w, preferably about 2 to 5% w/w, n gum; and
- about 0.2 to 10% w/w, preferably about 1 to 5% w/w, ascorbic acid.
[0033A] In a particular aspect, the present invention provides a l dressing
comprising at least a first layer and a second layer, wherein:
[0033B] - the first layer comprises honey in a dry, granular form; and,
] - the second layer comprises at least one pharmaceutically acceptable salt in
a dry, granular form, wherein the at least one salt is a carbonate (CO3-2) and/or bicarbonate
(HCO3-1) salt; and
[FOLLOWED BY PAGE 7a]
[0033D] - n at least one of the first and second layers further comprises at least one
c acid in dry, granular form, wherein the organic acid is additional to the organic acids
naturally occurring in honey.
BRIEF DESCRIPTION OF THE GS
The present invention will be further understood from the following detailed
description of an embodiment of the invention, with reference to the drawings in which:
Figure 1 is a graph of observed desloughing in vitro of a sample of pig skin over
time, with compositions of formulas (A) to (E) as denoted in Example 1; the concentrations of
[FOLLOWED BY PAGE 8]
sodium bicarbonate in honey by percentage weight in each of formulas (A) to (E) are
denoted as “HoneyMousse [concentration of NaHC03, % w/v]” in the legend;
Figure 2 is a graph of observed desloughing in vitro of a sample of pig skin over
treatment time, comparing the desloughing efficiency of Formulation (E) (as bed in
Example 1), compared with honey alone (control), papain ointment and Santyl® collagenase
ointment;
Figure 3 is a series of photographs of observed changes in vivo, in a myiasis
ulcer on a leg of a donkey, taken at Day 0, Day 7, Day 29 and Day 63, counting from the first
day of treatment as described in Example 1(ii)(a);
Figure 4 is a series of photographs of observed s in vivo, in an ankle
wound on a , taken at Day 0, Day 3 and Day 18, counting from the first day of
treatment as described in e 1(ii)(b);
Figure 5 is a series of photographs of ed changes in vivo, in a myiasis
ulcer on the girth of a horse, taken at Day 0, Day 16, Day 21 and Day 32, counting from the
first day of treatment as described in e 1(ii)(d); and
Figure 6 is a series of photographs of observed s in vivo, in a surgical
excision wound of a human male patient (following excision of a acanthoma), taken at
Day 0, Day 6 and Day 7, counting from the first day of treatment as described in Example
1(ii)(c).
ED DESCRIPTION OF EMBODIMENTS
The terms "comprise", "comprises", "comprised" or "comprising" may be used in
the present description. As used herein (including the specification and/orthe claims), these
terms are to be interpreted as specifying the presence of the stated features, rs, steps
or components, but not as precluding the presence of one or more other features, integers,
steps, components or a group thereof as would be apparent to persons having ordinary skill
in the relevant art.
The term “about” as used herein with respect to concentrations, pH or other
quantities is intended to indicate a variation of at least 10%.
As used herein (including the specification and/or the claims), the terms
“debriding” and “debridement” referto the removal of damaged, non-viable or necrotic tissue
from a wound, and the term “slough” refers to the shedding of non-viable or necrotic tissue
from living tissue. As used in herein, the terms “desloughing agent” and “debriding agent”
refer to agents and compositions that remove, or aid in the removal of, non-viable or necrotic
tissue from living tissue, by facilitating detachment of slough from living tissue within a
wound site.
The present invention is based on the finding that a composition sing
honey and one or more pharmaceutically acceptable mineral salts of ate (C03'2) or
bicarbonate (HC03'1) (the salts capable of reacting with (1) moisture and an acid, or (2) an
acidic solution, to form carbon dioxide), provides an unexpected significant enhancement of
the removal of non-viable tissue, that is far greater than observed for either honey alone or
carbon e alone. The removal of non-viable tissue may be for the purposes as a
desloughing, wherein the ition is used as a debriding agent, forthe purposes of
ing wound healing, or it may be for superficial ation of the epidermis to
cosmetically enhance skin appearance. The enhancement of wound healing and
therapeutic effect has been found to be far greater than would be expected from a simple
additive effect of honey and carbon dioxide used separately to treat a wound site.
Honey contains naturally occurring c acids, including gluconic acid, lactic
acid, acetic acid, butyric acid, citric acid, malic acid, pyroglutamic acid and ic acid.
Gluconic acid is present in the highest concentration (up to 1% w/v), as it is produced by the
oxidation of e by glucose oxidase, both of which are naturally occurring in honey.
Medical grade Manuka honey typically has a pH in the range of pH 3.2 to 4.5. The
concentration of total organic acids in Manuka honey from spermum ium ranges
from 0.17% w/v to 1.17% w/v. If desired, the pH of the honey may be further lowered by
addition of any of the above-noted acids that naturally occur in honey, as well as other food
grade or pharmaceutically acceptable weak organic acids such as ascorbic acid, and the
alpha y acids, glycolic acid, citric acid and mandelic acid. In a preferred embodiment,
gluconic acid and/or lactic acid, or salts thereof, may be added to the composition of the
invention, as both of these acids and their salts provide beneficial effects. In the case of
gluconic acid, it is capable of ing metal ions, which may help to inhibit oxidative
reactions that may othenNise damage healing tissue. In addition, both gluconic and lactic
acids are humectants and thus provide moisturizing properties. In another preferred
embodiment, the composition may further comprise ascorbic acid or a salt thereof. Ascorbic
acid and its salts act as idants and thus limit oxidate stress within the wound site,
thereby promoting wound healing.
In a preferred embodiment, the honey used to prepare the ition is medical
grade Manuka honey, with a minimum UMF rating of 10 (equivalent to crobial effect of
% phenol in water), a pH in the range of about 3.2 to 4.5, and a minimum methylglyoxal
concentration of about 150 mg/kg. Preferably, the total c acid content is in the range
of about 0.17-1.17% w/v, with gluconic acid being the primary organic acid.
The addition of a pharmaceutically acceptable l salt of carbonate (CO3'2) or
bicarbonate (HC02'1) to honey, initiates a reaction between the salt and the naturally
occurring moisture and acids within the honey that evolves carbon dioxide gas within the
honey. In a preferred embodiment, the ition according to one embodiment of the
ion is in the form of a foam or mousse, wherein the foam comprises fine bubbles
ed in carbon dioxide. A slight molar excess of the mineral salt to the naturally
occurring acids within the honey is added, such that the resultant composition has a pH that
is preferably in the range of about 6.3-7.4.
The above-noted composition may be used as a desloughing composition, or
debriding composition. The composition provides an elegant and simple method of covering
a wound site with a carbon dioxide enriched atmosphere, without requiring any specialized
equipment to introduce the carbon dioxide to the site of application. After applying, the
portion of the composition exposed to air may dry to form a thin skin that r aids in
sealing the carbon dioxide enriched atmosphere to the wound site. This also serves to seal
the wound site from the surrounding environment, protecting it from contaminants. In the
case where moist wound care is desired, the ition helps to help the wound site
ed. The composition readily fills and penetrates the wound site, delivering both
carbon dioxide and the honey to areas of the wound that would normally be difficult to
access. As noted above, the honey helps to draw out wound exudate by its strong osmotic
action on body tissue, and provides antimicrobial, anti-inflammatory and antioxidant effects.
The ition also provides a source for generating additional carbon dioxide:
as the composition comes in contact with moisture from body tissue, or wound exudate, the
excess l salt within the composition reacts with this moisture to form additional carbon
dioxide.
The composition has an adherent contact surface that allows it to bind to both
wet and dry wound surfaces, as well as wound dressings, which may be optionally applied
over the composition. As the pH of the composition can be adjusted to about 6.3 to 7.4, the
pH would be close to that of body tissues including epithelial and connective tissues, as well
as interstitial fluid. Consequently, the application of the composition to the wound site is not
expected to irritate or cause significant pain to the patient. The composition may be applied
by an unskilled practitioner, or it may be self-applied by the patient.
The composition may be reapplied as required during the course of wound
healing. It is expected that after the initial application, the composition will eventually lose
activity over time as the honey will be diluted by moisture or wound exudate, the carbon
dioxide comprised within the composition will gradually escape to the atmosphere, and/or
the excess bicarbonate or carbonate salt will be eventually be consumed.
In an embodiment, there is ed a system comprising the above-described
composition, and an isotonic diluent buffer solution. The ic diluent solution may be
used to dilute the composition to provide an irrigation solution that can be used to cleanse
and rinse out the wound site before fresh ition is applied. This may be done before
the l application of composition is applied to the wound, or it may be done during the
course of subsequent applications of the composition. In an embodiment, the diluent
solution comprises ascorbic acid, sodium bicarbonate, and sodium chloride. Preferably, the
diluent solution further comprises a surfactant and a pharmaceutically acceptable
preservative. The diluent solution can be used to dilute the composition by any degree, as
would be understood by persons skilled in the art. For example, in one embodiment, the
diluent solution can be used to dilute the composition to a ratio (the volume of composition to
the volume of diluent solution) of about 1:2 to 1:30. Any other on ratios within this range
are also contemplated, such as 1:2, 1:5, 1:10, 1:15, 1:20, 1:25 and 1:30, inclusive of all
ratios between these values. Various l devices may be employed to apply the wound
tion solution to the wound, including but not limited to: ing sponges, pulsatile
wound irrigation devices, mechanical spray irrigation s (including spray and vacuum
devices), squeeze bottle dispensers and the like.
Besides its use in promoting the healing of chronic wounds, the composition may
also be used to promote the healing of other medical concerns, for example, oral ulcers,
surgical , trauma , minor cuts, abrasions, burns, puncture wounds and
In another ment, the composition may be used as a veterinary wound
care agent, to promote wound healing in wild and domesticated animals. Such wounds may
include lacerations, abrasions, myiasis (fly bite) ulcerations, and burns resulting from
chemical, thermal or electrical exposure. For such nary uses, the composition may
further comprise a suitable insect repellant such as citronella, in order to limit insect contact
with the wound site.
It has also been discovered that the above-described composition is useful for a
variety of cosmetic applications. For example, it may be used for superficial exfoliation of
the epidermis to ically improve skin appearance.
The ition would also be used to improve the appearance of
hyperpigmented areas. This can be achieved by exfoliation to remove ted skin cells,
revealing less pigmented skin below.
In cosmetics, sodium bicarbonate is sometimes used as a ical exfoliant in
facial or body scrubs and it is also found in compositions that provide an antiseptic and
deodorant effect; in food es, sodium bicarbonate or sodium carbonate (both in pure,
solid form, or in aqueous solution) are sometimes used to break down protein, due to their
basic pH. However, sodium bicarbonate can be overly harsh as a mechanical exfoliant and
it can be irritating to the skin, and this effect would be common to any other mineral salts of
carbonate or bicarbonate. As well, ons of bicarbonate or carbonate salts are basic in
pH and would also be irritating or damaging to the skin. The above-described composition is
far superior to sodium bicarbonate alone, as it is provides a mild yet effective means of
superficial exfoliation of the epidermis without causing any irritation or damage to the skin.
As an ant, the composition is more effective than either honey alone, or mineral salts of
carbonate or bicarbonate.
The composition may also be used to enhance recovery from acne, as it provides
an antibacterial and anti-inflammatory effect, while at the same time, it ates the
epidermis and helps to clear infected pores. The composition may be applied as a mask
that is left on the skin for a short period of time, and then rinsed off.
In ison to other ly used cosmetic exfoliants including mechanical
exfoliants (e.g. cleansers containing small particles which act as abrasives; brushes, cloths
and sponges), and chemical exfoliants such as alpha and beta hydroxy acids, retinoids, and
topical acne ents such as benzoyl peroxide, the above-noted composition is non-
irritating and is well tolerated by most users, with low allergenic potential.
The composition may be also be used to manage and improve chronic skin
conditions including ichthyosis, psoriasis, seborrheic itis, atopic dermatitis and
. The composition forms an occlusive barrier on the skin, which provides
rizing and humectant s. The composition aids in exfoliation of the build-up of
dead skin cells, a common e in all of these skin conditions. At the same time, the
composition serves to calm inflammation, inhibit secondary microbial infections, and promote
healing of the skin.
In addition to the above, the composition may be provided in the form of a lip
balm or lip ointment. As a lip balm, the composition enhances exfoliation of dried skin from
the lips while moisturizing the lips. Both of these properties are highly useful to users in cold
and/or dry climates. The composition also promotes the healing of cold sores and fever
blisters, which are symptoms exhibited by patients ing from other es or
infections, such as Herpes Simplex l infection.
In an embodiment, the mineral salt is a pharmaceutically acceptable, water
e salt, preferably a carbonate and/or bicarbonate salt, and wherein the salt s
carbon dioxide (C02) gas upon contact with an acid and water. In a further embodiment, the
one or more salts are selected from sodium bicarbonate, ammonium onate, potassium
bicarbonate, calcium bicarbonate, sodium carbonate, potassium carbonate and
combinations f. In a preferred embodiment, the salt is sodium bicarbonate.
In another embodiment, the honey is medical grade honey. In yet another
ment, the honey is medical grade honey derived from bees that have fed primarily or
exclusively on plants of Lepz‘ospermum sp. In a preferred embodiment, the honey is
obtained from the hives of bees that have fed exclusively on Lepz‘ospermum scoparium,
commonly referred to as Manuka, New Zealand tea tree, broom tea tree or simply tea tree.
Honey of this source is also commonly referred to as Manuka honey.
In an embodiment, the composition is ed in the form of a foam or mousse,
wherein said foam or mousse comprises bubbles or cells that further comprise carbon
dioxide gas. The foam is preferably capable of generating additional carbon dioxide gas
upon contact with acid and moisture. In another embodiment, the composition is provided
as an ointment, cream, lotion, gel or balm, wherein said ointment, cream, lotion, gel, or balm
is capable of generating carbon dioxide gas upon t with acid and re. lfthe
composition is provided in the form of an ointment, cream, lotion, gel or balm, it may further
comprise bubbles or cells that further comprise carbon dioxide gas.
Thickening agents may be added to the composition to provide a thicker or stiffer
consistency, which may be desirable under various stances. An example would be
the care required for c wounds since, in such cases, the composition must stay in
place for longer periods of time. Chronic wounds include but are not limited to ulcers,
surgical wounds, and burns and those comprising necrotic tissue. Thickening agents may
also help to absorb moisture such as wound exudate, thus preventing dilution of the
composition, and extending the activity of the composition. Examples of suitable thickening
agents include but are not d to: polysaccharides such as starches, agar, alginic acid
and salts thereof (e.g. sodium alginate), eenan, pectin, beta glucan, and natural gums
such as xanthan gum, gum arabic, gum ghatti, guar gum, locust bean gum and combinations
thereof. In a preferred embodiment, the thickening agent is xanthan gum. Other suitable
thickening or gelling agents will be known to persons skilled in the art.
Suitable surfactants may also be added to the composition to aid in ration
of non-viable tissue, and thus promote the debriding or desloughing effect. An e of
such a surfactant is sodium lauryl sulfate. In an embodiment, the composition comprises
about 0.0001 to 0.1% w/v sodium lauryl sulfate. Other suitable surfactants will be known to
persons skilled in the art.
In another embodiment, the composition may further comprise one or more
proteolytic enzymes (proteases). The protease provides enzymatic debridement to the
composition and further enhances the activity of the composition for degradation and
l of non-viable or ic body tissue. Autolytic debridement, as brought on by
application of honey, is considered to be slow , compared to enzymatic debridement.
Thus, the addition of more or more proteases may extend the activity of the composition.
The proteolytic enzyme may be plant-derived proteases, such as , actinidin,
bromelain, ficain, or cucumisin, or bacteria-derived proteolytic enzymes. In a red
embodiment, the composition comprises actinidin. In another preferred embodiment, the
composition comprises a plant extract that ses actinidin. The plant extract is
preferably kiwi fruit extract, which contains actinidin. The plant proteases may be added to
the ition in crude or purified form. If the composition comprises one or more plant-
derived proteases, the composition may additionally n antimicrobial agents such as
methylglyoxal or its sor, 1,3-dihydroxyacetone.
In yet another embodiment, the one or more proteolytic s, if present, are
preferably provided in their zymogen form. As used herein, the term en" will be
understood to mean an inactive form of an enzyme that is converted to its active form by
WO 74159
action of an activating agent. Such activating agent may include an acid, another enzyme or
a combination thereof.
In orderto maintain d properties and to se storage time (shelf life)
over prolonged periods of time, the composition may be supplemented with one or more
pharmaceutically acceptable preservatives as known in the art. Examples of vatives
that may be used in the t invention include methyl paraben, propyl paraben, butyl
paraben, imidazolidinyl urea, tetradecyl-trimethyl ammonium bromide mide®), sodium
benzoate, potassium sorbate, thymol, inopropyl biguanide, and combinations thereof.
Various other preservatives will be known to persons skilled in the art.
As described above, in an embodiment of the present invention, the composition
comprises honey that is produced by bees that have fed mainly or exclusively on
spermum plant species. Preferably, the honey is Manuka honey produced from
Lepz‘ospermum ium. In another embodiment, the Manuka honey has of a pH of about
3.2 to 4.5 and a minimum methylglyoxal concentration of about 150 mg/kg. In one
embodiment, particularly for wound treatment, the composition of the invention comprises
about 80% (w/v) or more of honey.
In another ment, the composition is in the form of a foam or mousse,
preferably comprising cells or bubbles of carbon dioxide. The composition may also be in
the form of a gel, lotion, cream, ointment or balm. These other forms may further comprise
cells or bubbles comprising carbon dioxide.
In yet another embodiment, the pharmaceutically acceptable salt is: sodium
carbonate (Na2C03), potassium carbonate (K2C03), um carbonate ((NH4)2C03),
sodium bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), ammonium bicarbonate
((NH4)HC03) or any combination f. In one embodiment, the pharmaceutically
acceptable salt is sodium bicarbonate 3).
The pharmaceutically acceptable salt may be present in the composition at about
2.5 to 20% w/v of the composition. In one aspect of the invention, the salt is present at
about 5 to 15% w/v of the composition. In another aspect, the salt is present at about 7.5 to
12.5% w/v of the composition. In one aspect of the invention, the concentration of the salt
may be varied according to the desired use of the composition. For example, if the
composition is for use in treating a wound with necrotic tissue and malodor, the salt (e.g.
sodium bicarbonate) concentration may be 12.5% -15.0%. lfthe composition is for use in
treating a wound after all necrotic tissue has been removed and is in later stages of
granulation, the salt concentration may be 0%. lfthe composition is for use in
treating a wound with completed granulation and where thelialization has started, the
salt concentration may be 2.5%-5.0%. Thus, as would be understood by persons skilled in
the art, a higher salt concentration would be preferred when the composition is used in a
wound at an early stage of g. However, it will also be understood that such preferred
embodiment of the invention is not intended to restrict the concentration of the salt
component based on the state of the wound.
In an embodiment of the t invention, the composition may further se
one or more organic acids. For example, the organic acids may be: gluconic acid, lactic
acid, acetic acid, butyric acid, citric acid, malic acid, utamic acid, succinic acid,
ascorbic acid, glycolic acid, lactic acid, citric acid, mandelic acid or any ation thereof.
The one or more organic acids of the composition would be understood to be in addition to
those acids naturally occurring in honey. In one embodiment, the organic acid used in the
composition is ascorbic acid. The organic acids added to the composition may be present at
a concentration of about 0.2 to 10% w/v of the composition. In one aspect, the acid is
present at a concentration of about 1 to 5% w/v of the composition. Generally, the
concentration of the organic acid would be that needed to adjust the pH of the composition
from about 5 to about 7.4 and, preferably, from about pH 5.5 to about 6.5. More preferably,
the pH of the composition is adjusted to be about 7 to 7.4. As would be understood, where
the concentration of the carbonate and/or bicarbonate salt is high, resulting in a greater
amount of C02 e, a higher concentration of the c acid would be needed to adjust
the pH of the composition to the aforementioned desired levels.
In another embodiment of the present invention, the composition may further
comprise one or more thickening . For example, the thickening agents may be:
polysaccharides, starches, agar, alginic acid and salts thereof, carrageenan, pectin, beta
glucan, xanthan gum, gum arabic, gum ghatti, guar gum, locust bean gum, or any
combination thereof. In one embodiment, the composition comprises xanthan gum. The
thickening agents may be present at a concentration of about 0.2 to 6% w/v, with the
tration being dependent upon the desired viscosity of the composition. For example,
a sufficient amount ofthickening agent may be incorporated to provide a viscosity, at skin
ature, that is sufficient to cover and seal the site of application (e.g. the wound area)
so as to provide an environment enriched in C02 and reduced in 02. In one aspect, the
thickening agents may be present at a concentration of about 1 to 5% w/v. In another
, the thickening agents may be present at a concentration of about 2 to 5% w/v.
In yet another embodiment, the composition may further comprise sodium lauryl
e. Sodium lauryl sulfate may t in the composition at a concentration of about
0.0001 to 0.1% w/v.
In another embodiment, the ition further comprises one or more
proteolytic s. For example, the proteolytic enzymes can be: papain, actinidin,
bromelain, ficain, cucumisin, bacteria-derived proteolytic enzymes, or any combination
thereof. The enzyme may be provided as an extract of the plant or bacteria that comprises
one or more ofthe above-noted enzymes. In a r embodiment, the enzyme is actinidin.
din may be provided in kiwi fruit or an extract thereof. Such an extract includesjuice of
the kiwi fruit, or a concentrate thereof.
In yet another embodiment, the composition further comprises one or more
preservatives. For example the preservatives may be: methyl paraben, propyl paraben,
butyl paraben, imidazolidinyl urea, tetradecyl-trimethyl ammonium bromide mide®),
sodium benzoate, potassium e, thymol, polyaminopropyl biguanide, or any
combination thereof.
In an embodiment of the present invention, the composition has an osmotic
concentration at least 14.5 times the osmotic concentration of human blood.
In another aspect of the present invention, there is provided a use of the
composition as described herein, as a desloughing agent or a debriding agent, a wound
treatment agent, a veterinary wound care agent, and for the ent of chronic skin
disorders. Such skin disorders may comprise, for example: ichthyosis, psoriasis, seborrheic
dermatitis, atopic dermatitis, and eczema. There is also ed a use of the composition
as a cosmetic skin exfoliant.
In yet another aspect of the present invention, there is provided a system of
wound treatment comprising the composition according to any of the above-described
embodiments and an isotonic diluent solution, preferably of about pH 7, comprising: about
0.015 M ascorbic acid; about 0.015 M sodium bicarbonate; and, about 0.12 sodium chloride;
- wherein the isotonic t on is used to dilute said ition at a
minimum ratio of 1 part said composition to 2 parts said diluent solution (1:2), thereby
forming a wound irrigation solution; and wherein the wound tion solution is used to
irrigate a site of ent on a patient before application of said composition.
An advantage of the invention is that is provides an unexpected, and significant
enhancement of the removal of non-viable tissue, that is far greater than observed for each
of honey, carbon dioxide, and mineral salt of ate (C03'2) or bicarbonate (HC03'1). The
enhancement of wound healing and therapeutic effect is also far greater than would be
expected from a simple additive effect of honey, carbon e, and mineral salt of
carbonate or bicarbonate, used separately to treat a wound site.
Another age of the invention is that it may be used as a desloughing or
debriding agent, for the purposes of ion of wound healing, or it may be for superficial
exfoliation of the epidermis to cosmetically enhance skin appearance.
Yet another advantage of the ion is that it provides an elegant and simple
method of covering a wound site with a carbon dioxide enriched atmosphere, and honey,
both of which provide numerous beneficial effects in the promotion of wound healing,
including but not d to:
- providing a hyperosmotic nment (also referred to as an environment of
negative osmotic pressure) that draws out and absorbs wound exudate;
- providing a means of stimulating oxygen and irculation to the wound site;
and,
- providing a carbon dioxide-enriched micro-climate over the wound that
discourages growth of aerobic ia.
Another advantage of the invention is that it is mild, with a pH that can be
adjusted close to the pH of interstitial body fluids and body tissues including epithelial and
connective tissues; uently, the application of the composition to the wound site is not
expected to irritate or cause significant pain to the patient.
Yet another advantage of the invention is that it is simple and does not require
specialized equipment to use or apply: the composition may be applied by an unskilled
practitioner, or it may be self-applied by the patient.
Another advantage of the invention is that it may be used on human patients or it
may also be used to promote wound healing in wild or domesticated animals.
WO 74159 2014/051124
Another advantage of the invention is that it may be used for superficial
exfoliation ofthe epidermis to cosmetically improve skin appearance. It may also be used to
enhance recovery from acne, as it provides an antibacterial and anti-inflammatory effect,
while at the same time, it exfoliates the epidermis and helps to clear infected pores. In
addition, the invention may be also be used to manage and improve chronic skin conditions
including ichthyosis, psoriasis, heic dermatitis and eczema.
In all cases, an advantage of the invention is that it is much milder than known
ent s, with low irritation and allergenic ial, while still providing effective
treatment and management of the above-noted l concerns.
Other and further advantages and features of the invention will be apparent to
those skilled in the art from the following detailed description of an embodiment thereof,
taken in conjunction with the accompanying drawings.
In one , there is ed a treatment kit comprising the honey component
and the carbonate and/or bicarbonate salt component of the composition, as discussed
above. Optionally, the kit may include any necessary instructions for forming and using the
composition and/or any variety of containers or vials etc. for mixing the components to form
the composition.
In one aspect, the honey component of the composition is provided in dry or
powder form. Similarly, the carbonate and/or bicarbonate salt component may also be
provided in dry or powder form. As would be understood, providing the components of the
invention in dry form allows for extended shelf life. In the case of dried or powdered honey
and dried or powdered carbonate/bicarbonate salt(s), the two components can be provided
in a kit comprising one or two containers or packages for the honey, carbonate and/or
bicarbonate salt, or a mixture thereof. In such case, the kit may further comprise a container
or package containing a volume of water, which can be used to form the composition
described above. As mentioned above, the kit may include a container into which the
dry/powder components are combined with the water. In one example, the container may
contain the necessary volume of water and the dry honey and salt components may be
provided in a package or . atively, the container may be provided in an empty
state, prepared to receive the dry/powder components and the required volume of water
from an able source.
In another aspect, the dried honey and carbonate/bicarbonate salt components
can be combined into a dressing or other such application medium. Once , the
components of the composition would become wetted and y activated. In one aspect,
the dressing would be adapted to form a foam or mousse as described above. The wetting
of the dressing can be ed by adding water or by using the natural e originating
from a wound.
In one aspect, the above mentioned ng may incorporate coated honey
crystals, which are activated by the high pH of the bicarbonate once hydrated by added
water or would ions. Such coating may be provided by microencapsulation of the
dried honey.
In another , the dried honey, the carbonate/bicarbonate salt and the acid
components can be combined together in dry form in a single airtight pouch. In one aspect,
the honey may be coated (or microencapsulated) to allow for a release under certain
conditions. In r aspect, neither of the ingredients would need to be coated as they
would be inert in their dry state. The powder composition, such as the non-coated particles,
can then be applied to a region to be d, such as a skin ulcer, and then covered to
allow the treatment phase to take place.
In the above description, the use of natural honey, in either liquid or dry (and/or
encapsulated) form, has been discussed. However, in further aspects, such natural honey
can be replaced with a synthetic honey or a honey substitute. For example, corn syrup of a
suitable viscosity can be used instead of honey to entrap carbon dioxide released at the
point of use due to the reaction of organic acid(s) and sodium bicarbonate. Similarly,
suitable compositions of invert sugars such as corn syrup of such viscosity and low water
content as to approximate honey (86% sugars) in a ratio of 55% fructose and 45% glucose
may be used as alternatives to honey in necrotic wound and healing formulations as
described above.
Examples
Aspects of the ion will now be described with reference to s
examples. It will be understood that the following examples are provided to illustrate the
present invention and are not intended to limit the scope of the invention in any way.
Example 1: Preparation and Testing of Treatment Compositions
(i) Preparation ofTreatment Compositions
The following compositions were prepared. Medical grade Manuka honey
derived from Leptospermum scoparium (Links Medical LLC) was used to prepare the
compositions, wherein the medical grade honey had a pH 3.63, and was defined as having
an activity equivalent to 16% phenol, also referred to as level 16 on the 20 point Unique
Manuka Factor (UMF) scale. Either sodium bicarbonate or potassium bicarbonate could be
used in the formulations noted below. The results shown below are for formulations
ed with sodium bicarbonate.
Table 1: Compositions of honey and sodium bicarbonate (% w/w of total)
Honey Sodium bicarbonate As noted in Figure 1
(% wlw) (NaHCOs) (% wlw)
B 95.0 5.0 6.95 ousse 5%
C 92.5 7.5 7.0-7.2 HoneyMousse 7.5%
E 87.5 12.5 7.2 HoneyMousse 12.5%
Control 100.0 0 3.63 Honey Control
Upon addition of sodium bicarbonate to honey, a composition in the form of a
stable foam was , sing minute cells, each cell enclosing a carbon-dioxide
enriched atmosphere.
ii In Vitro Testin of in /Deslou hin Efficienc
Figure 1 shows the debriding or desloughing efficiency of each of the above
compositions, when applied to a sample of pig skin in vitro, at room temperature. Since the
melanin pigment in pig skin is located primarily in the basal layer of the epidermis,
ment of the dark-coloured epidermis reveals the amber-coloured dermis beneath.
Therefore, detachment of the epidermis may be easily visualized and was taken as a marker
of successful debriding or desloughing of the epidermis from the dermis. Squares of pig
skin, 2.5 cm2 in area, were treated with each of formulations (A) to (E) of Table 1, ing
to the ing protocol, repeated every 12 hours: (1) wash with water, (2) raph and
quantify debrided area and (3) reapply 1.5 g of formulation to each square of pig skin (Le.
approximately 0.24 g per 1 cm2). The area of the revealed dermis was quantified on a grid
and calculated as a percentage of the total area of the sample, at each 12 hour application
point.
As shown in Figure 1, there was an incremental increase in debriding or
desloughing efficiency, dependent on sodium bicarbonate concentration, which reached a
plateau at around 12.5% w/w sodium bicarbonate, in Formulation (E).
Formulation (E) was then compared with the debriding efficiency of commercially
ble debriding compositions, Santyl® collagenase ointment (Smith & Nephew, Inc.) and
Kovia® papain-urea ointment (521,000 units papain activity per gram ointment; Stratus
Pharmaceuticals Inc). Debriding/desloughing efficiency was measured in vitro on pig skin,
according to the same experimental protocol as described above. Figure 2 shows the
results of the comparison of in vitro debriding efficiency of ation (E), ning 12.5
% w/w sodium bicarbonate, compared with commercially available ing compositions,
Santyl® collagenase ointment (Smith & Nephew, Inc.) and Kovia® papain-urea nt (as
above; Stratus Pharmaceuticals Inc).
As shown in Figure 2, Formulation (E) comprising 12.5% w/w sodium bicarbonate
provided faster and more effective debridement of the pig skin, compared to either Kovia®
papain-urea ointment or Santyl® collagenase ointment.
(iii) In Vivo Tests of Debriding/Desloughing Efficiency
(a) Treatment of equine myiasis ulcer on donkey
A donkey with a large myiasis tion on lateral aspect of right front knee was
treated with Formulation (E).
The ulceration wound was 8.6 cm wide by 9.4 cm high and ted with heavy
encrustation of blood. The wound was cleansed with 3% hydrogen de and irrigated
with sterile saline on Day 0 and was treated to e and heal by secondary intention. The
study consisted of daily removal of the dressing and saline irrigation followed by application
of the following at the given time periods.
Day 0: Pre-Debriding Ointment (as provided in US. Patent Application
Publication No. 20130085461) was applied for 24 hours. t temperature was 32-
°C. Dressed with non-stick ng and d with leg pad and held with cloth strap
and Velcro® closure.
Days 1-7: Kiwi fruitjuice concentrate (containing naturally-occurring actinidin)
plus formulation A (Leptospermum scoparium (Manuka) honey and 2.5% sodium
bicarbonate, pH 6.35);
Days 8-29: Medical grade Manuka Leptospermum scoparium honey only, pH
3.63 (Links Medical LLC);
Days 30-68: Formulation E spermum scoparium honey and 12.5% sodium
bicarbonate, pH 7.2)
The composition ofthe Pre-Debriding Ointment was as follows (also as provided
in US. Patent Application Publication No. 85461):
Ingredient Concentration (% WNV)
Urea 25.00
Waxes and mineral oils 10.00
n-propanol 4.00
glucose (USP grade)
During debriding (days 1-7), treatment was daily. After debriding during
granulation and remodeling of granulation tissue (days 8-29), ent was every 3 to 4
days. During dermal and epidermal tissue construction and migration, to wound closure, the
treatment composition was applied every 4 to 7 days. Photographs were taken during
treatment; Figure 3 shows photographs taken on days 0, 7, 30 and 68 of the treatment.
ations at the end of each stage of treatment are as provided below.
Following the briding ointment treatment for 24 hours at 32-35°C on heavy
eschar and necrotic tissue, the subsequent use of kiwi fruitjuice enzyme (actinidin) in honey
mousse was able to debride the wound in 4 days and promote rapid granulation. Debriding
was continued with the treatment composition to day 7 to ensure complete ing. At day
7, the wound appeared to be vigorously granulating with good vascularity and has filled the
wound t. Medical grade Manuka (Leptospermum ium) honey alone was used on
days 8 to 28, and produced good granulation development and remodeling up to Day 30. At
day 30, epithelial migration continued to close the wound. Granulation tissue is also
continuing to remodel and vascularize and innervate.
Formulation (E) from Table 1 continued the healing with epidermal migration
starting around day 30. Formation of new epithelium was about 75% complete at 49 days,
about 90% complete at 63 days, and about 93% complete at 68 days. This rate of
epithelialization appeared to be slightly delayed and indicates that the honey mousse (12.5%
sodium bicarbonate) may be best suited forthe debriding and granulation phase of wound
heaHng.
] (b) Treatment of equine myiasis ulcer on donkey
] A donkey with ankle wounds was presented fortreatment. Myiasis tions
2.5 cm x 1.5 cm were located on the anterior aspect of the front right ankle. The donkey had
been plagued by fly bite irritated skin resulting in ulceration and erosion of mis and
dermis. Left uncovered and untreated, this ulceration would enlarge rapidly as did the
ulceration on his knee above.
The affected area was treated with Formulation (A) and then Formulation (E),
according to the following protocol. Photographs were taken during ent; Figure 4
shows photographs taken on days 0, 3 and 18 ofthe ent. Observations at the end of
each stage of treatment are as provided below.
Day 0: Pre-Debriding Ointment (as noted above in Example 1(iii)(a); as provided
in US. Patent Application Publication No. 2013/0085461) was d and left in place for 24
hours. Ambient temperature was 35°C.
] Day 1-3: Kiwi fruitjuice with actinidin enzyme, 40 units/g, was added to
formulation (A) (Manuka Leptospermum scoparium honey and 2.5% w/v sodium
bicarbonate), and an amount sufficient to cover wound was applied to the wound site. For 3
days, the wound was washed with saline and the non-stick dressing was changed every 24
hours. The y dressing was with cotton wrap with Velcro® closure. Debriding was
considered complete on day 3. The development of new granulation tissue was observed
on day 3.
] Day 4-18: The wound site was treated with Formulation (E) (Manuka
Leptospermum ium honey and 12.5% sodium bicarbonate). Honey mousse left in
place for 3-4 days at a time. On day 18, the wound was observed as being fully closed.
(c) Treatment of equine myiasis ulcer on horse
A horse with a large girth (chest) wound from myiasis (fly bite) ulcerations
measuring 10 cm x 9.5 cm x 1.2 cm deep, was ted for treatment. The wound site was
surgically debrided and treated with Formulation (E) (Manuka honey and 12.5% w/w sodium
onate) until closure according to the following ol.
The horse was given appropriate sedatives and was then positioned on its back.
The chest wound, found just distal to the front legs, was cleansed with betadine, and the
area surrounding the wound site was shaved. The necrotic tissue mass was ally
excised down into the grey fibrous connective tissue over the sternum, approximately 1.5cm
deep. The wound site was irrigated with sterile saline and Formulation (E) was applied to
non-stick pads and placed on the wound. A secondary dressing of a disposable diaper was
used to further secure Formulation (E) in place. On subsequent dressing changes, the
wound was irrigated, photographed and Formulation (E) ied on non-stick ngs
held in place with a custom-made sling created by the owner which kept the dressing secure
for 3-7 days at a time. Photographs were taken during treatment; Figure 5 shows
photographs taken on days 0, 16, 21 and 32 of the treatment. ations at the end of
each stage of treatment are as provided below.
Formulation (E) was effective for debriding the wound margin tissue that became
necrotic after the surgical excision, and was a strong stimulator of granulation and
remodeling. By day 16, the wound had finished granulation and was remodeling well out to
the edges. By day 21, epithelial migration had started and it was decided to ue
application of Formulation (E) to wound closure, in order to get a second assessment of its
effect during this phase. The wound closed on day 32, well within normal time frame. The
new epithelium appeared soft and loosely organized, as observed during the treatment
bed in Example 1(iii)(a).
2014/051124
(d) ent of al excision wound on human male patient
A human patient, male, age 69 years, in good general health, was presented with
a skin pathology appearing to be a classic keratoacanthoma on his right dorsal forearm. The
keratoacanthoma lesion was approximately 1 cm in diameter with a central crater, raised,
with no erythema. A shave biopsy was taken of the raised portion, approximately 1.4 x 1.3 x
0.2 cm in size, with an eccentric 0.9 x 0.7 cm white and brown lesion. At excision, the
ary bleeding was managed with electrocautery. The shave biopsy specimen was sent
out for pathology analysis.
The surgical wound was closed by secondary intention and treated daily with
Formulation (E) ng the day after the on. The wound cavity was filled with
Formulation (E) and d with an island type secondary bandage. At each daily dressing
, the wound was irrigated and re-dressed with ation (E). The treatment was
halted on day 7, when the pathology analysis found that the biopsy as comprising squamous
cell carcinoma, invasive and well differentiated, present at the deep margin. Photographs
were taken during treatment; Figure 6 shows the photographs taken on days 0, 5 and 7 of
the treatment. ations at the end of each stage of treatment are as provided below.
On day 0, shave biopsy and electrocautery produced a surgical excision wound
site. The wound site was dressed with triple otic ointment by the attending physician
and covered with non-stick pad with papertape. On day 4, formation of granulation was
proceeding and the wound site appeared to be approximately half filled. By day 6, the
granulation phase had completely filled the wound site, and the inflammatory response has
subsided. By day 7, it was observed that rapid debriding of cautery point necrotic tissue had
occurred, and granulation tissue had filled the wound site, with indications of angiogenesis.
The patient stated that there was no discomfort with the use of Formulation (E)
from a very slight tingling sensation starting about 10 minutes after application and lasting
about 10 minutes during the first two applications. This minimal ion compared
favorably against the stinging and burning sensations experienced by users of commercially-
available tic debriding compositions such as papain-based debriding ointments.
Example 2: System for Wound Treatment
As an example, Formulation (E) of e 1 was diluted with an isotonic diluent
buffer solution as follows:
2014/051124
Table 2 (a): Composition of lsotonic Diluent Buffer Solution
Buffer Solution Ingredient
Ascorbic acid 0.015 M
Sodium bicarbonate (NaHC03) 0.015 M
Sodium chloride (NaCl) 0.12 M
Undiluted Formulation (E) has an approximate osmolarity (also referred to as
osmotic tration) of 14.5 times greaterthan human blood. Formulation (E) of Example
1 was d with the isotonic diluent solution of Table 2(a), at the following dilution factors
provided in Table 2(b) below, with the corresponding resultant osmolarity compared to
human blood.
Table 2 (b): Dilution Factors
Dilution factor Resultant hyperosmolarity of diluted
(Formulation (E) : t solution) formulation compared to human blood
As noted above, the hyperosmolarity of the resultant solution was the osmotic
concentration of the resultant solution when compared to human blood. For example, a
solution diluted 1:2 resulted in a solution that had an osmotic concentration 7.2 xthe osmotic
concentration of human blood.
To each of these diluted solutions of Table 2(b), the ing compounds were
added to provide the final finished wound irrigation ons.
Table 2(C): ves to diluted solution
Additive Final concentration in solution
polyaminopropyl ide 0.00003% w/v
Disodium EDTA 0.025% W/V
The resultant diluted compositions were used as wound tion solutions, i.e. to
te the wound before applying a formulation of Example 1 (undiluted) forthe first time to
a wound site), or while replacing applications of the formulations of Example 1 to a wound
site with an application of fresh formulation.
Various medical devices may be ed to apply the wound irrigation solution
to the wound, including but not limited to, monofilament debriding sponges, pulsatile wound
tion devices, mechanical spray irrigation devices (including spray and vacuum devices),
and squeeze bottle dispensers.
Example 3: Cosmetic Formulations
(i) Sample Preparation
The following compositions, (a) and (b), for use as cosmetic formulations, were
a Moisturizin lotion with 12% w/w sodium bicarbonate and 5% w/w hone
Each of phases A, B, C and D were blended to homogeneity and heated to the
specified temperature range before final ng of all phases.
Potassium sorbate 0.2 2
Sodium benzoate 0.2 2
——-—
——-—
(45-50°C) Honey (Manuka, medical grade or r)
Phase D Benzyl alcohol
( 35-40°c ) Silk amino acids
TOTAL : m1000.000
b Moisturizin lotion with 5% w/w sodium bicarbonate and 5% w/w hone
Each of phases A, B, C and D were blended to homogeneity and heated to the
specified temperature range before final blending of all phases.
Phase A Purified water 54.5 545
(70-75°C) ol® 940 1.5 15
——-—
——-—
(45-50°C) Honey (medical grade, Manuka or regular)
°C) Silk amino acids
——-—
——Im-m
——-—
[ii] In Vivo Test
A female patient ing from severe ichthyosis was a test subject. Previously,
she had been using a urea and alpha hydroxy acid skin lotion (Extra Strength Body Lotion,
Dermal Therapy Inc.) for several years, in order to manage the symptoms of ichthoysis. The
patient applied approximately 2 g of the moisturizing lotion as provided in Example 2(i)(a)
above, comprising 12% sodium bicarbonate and 5% honey, to an affected area on one arm,
twice daily, for a period of two weeks. She observed a comparable ement to her
symptoms as with the actic acid cream.
Although the invention has been described with reference to certain specific
ments, various modifications thereof will be apparent to those skilled in the art
without departing from the purpose and scope of the invention as outlined in the claims
appended hereto. Any es ed herein are included solely forthe purpose of
illustrating the invention and are not intended to limit the invention in any way. Any gs
provided herein are solely forthe purpose of illustrating various aspects of the invention and
are not ed to be to limit the invention in any way. The disclosures of all prior art
recited herein are incorporated herein by reference in their entirety.
Example 4: Wound Dressing Incorporating Dpy Components
This example serves to illustrate a wound dressing incorporating Manuka honey
in the form of freeze dried granules, sodium bicarbonate powder and ascorbic acid crystals.
Method
1) Saturate sodium bicarbonate in high fructose corn syrup at 40 °C and saturate
the ng. Dry with 8-ply rayon/polyester layer of dressing on non-stick conveyor belt with
cellulose coated layer on top, using warm (40 °C) air until completely dry and binding the two
layers together.
2014/051124
2) Blend ic acid crystals and Manuka honey freeze dried granules (pH
3.6-4.5) in either a ing or healing formulation proportion and coat with EastmanTM
Cellulose Acetate Phthalate (CAP) using acetone:water (97%:3%) as the CAP solvent.
Spread the wet slurry of honey granules and ascorbic acid crystals onto “cellulose tissue”
dressing surface, and allow to evaporate to dryness under negative air flow. Sodium
bicarbonate is less than 0.2% soluble in acetone, so almost none will be dissolved.
3) When dried, seal the dressing in a typical dressing sleeve and irradiate to
sterilize.
More specifically, the method of this example involves the following. Micro-
encapsulate freeze-dried Manuka honey granules blended with ascorbic acid crystals
(pH3.6-4.5) in Cellulose Acetate Phthalate (CAP) and adhere the encapsulated mixture to a
cellulose tissue layer of a gauze dressing. CAP is lly used for pharmaceutical
encapsulation to produce an enteric coating that s dissolution when in an acid
environment, but dissolves when exposed to neutral to alkaline solution. Adhere sodium
bicarbonate to the outer rayon/polyester layer of the gauze dressing. Since the wound fluid
is absorbed by the dressing, the dissolving sodium onate solution (pH 7-8) will cause
dissolution of the CAP coating and release the honey and ascorbic acid. The honey is
extremely hygroscopic and will immediately absorb and rehydrate with wound fluid water to a
honey consistency (about 14% water). The c acids in the honey and ascorbic acid will
react in the wound fluid water with dissolved sodium bicarbonate to release carbon dioxide
which infuses the now fluid honey to create a foam.
Excess carbon dioxide is released from the non-occlusive gauze dressing.
Occlusive adhesive border dressings should be avoided as they could inflate or even
dislodge with carbon dioxide pressure.
The advantage of the sodium bicarbonate-fructose:glucose impregnation of the
ng is that it binds the sodium bicarbonate to the dressing (thereby ting the
powder from sifting through the dressing fabric) and it ts a saturated sodium
bicarbonate solution in wound fluid to the necrotic tissue in the wound for maximum
loosening, softening and detachment activity. The undissolved sodium bicarbonate in the
dressing acts as a reserve to continue to ve over time just as it does in fluid honey
model. The CAP coating of the hygroscopic honey es and ascorbic acid causes
same to be adhered to the ng and prevents them from pre-maturely absorbing water
and ng a longer shelf-life even with normal dressing ures. The CAP coating
withstands prolonged contact with acidic environments (the acidic honey and ascorbic acid),
then dissolves on contact with slightly acidic (pH 6.2) to neutral (pH 7-8) solutions.
Initially, the high fructose corn syrup/sodium bicarbonate gel produces negative
osmotic re as it hydrates, drawing in even more wound fluid and atmospheric
moisture. Then the sodium bicarbonate dissolved in the wound fluid (pH 7-8) dissolves the
CAP g and releases honey and ascorbic acid. The freeze dried honey granules then
e and increase the ve osmotic pressure entally. Because the sodium
bicarbonate reaction with acid is driven by the ng carbon dioxide gas, the equilibrium is
forced strongly in the direction of continued reaction until all the available sodium
bicarbonate in the expanding “wet” area of the dressing is used up. The mechanism is self-
regulating based on available wound fluid. This mechanism will work for both the “Debriding
and the g” formulations.
Example 5: ve Osmotic Pressure Dressing for Treating Necrotic
Wounds
Description: This dressing, or medical device, referred to as MANUKA—NW ,is
used to soften and facilitate removal of necrotic wound tissue using MANUKA honey (100%
permum scoparium honey from New Zealand). MANUKA-NW is super-saturated with
sodium bicarbonate for necrotic tissue detachment, and pH adjusted to neutral with Vitamin
C to ze autolytic debriding enzyme activity. MANUKA-NW Activator (sodium
bicarbonate and Vitamin C) is mixed with MANUKA honey at Point-Of—Use to generate
carbon dioxide which foams the viscous honey. The high sugar level of MANUKA-NW
provides Negative Osmotic Pressure to draw wound fluid and autolytic cleansing to the
wound.
The following are some ts of the activated MANUKA-NW :
1) lmproves removal and application at dressing changes, since it is less sticky
than honey.
2) Absorbs and/or lizes wound malodors with sodium bicarbonate.,
3) Expands into difficult-to-reach ined or tunneled necrotic areas of the
wound to provide moist wound environment.
4) Provides neutral pH needed for optimal autolytic debridement.
WO 74159
5) Provides a temporary C02 rich here over the wound to discourage
growth of aerobic ia.
6) Manuka honey supersaturated with sodium bicarbonate rapidly loosens,
softens and detaches necrotic epidermis and dermis tissue.
The Activated MANUKA NW is applied to the wound containing necrotic tissue
and wound debris, covered with gauze (which may be supplied as part of the kit), then
secured in place with a suitable secondary dressing or wrap.
] The contents of the kit could ably comprise:
1) 0.5oz. (14g) sterile 100% Manuka (Leptospermum scoparium) Honey in a
flexible tube with foil seal under threaded cap.
2) tor: 0.55g ascorbic acid and 2.35g sodium bicarbonate powder in sealed
container.
Example 6: Negative Osmotic Pressure Dressing for Healing Wounds
Description: This dressing, or medical , referred to as MANUKA N.O.P.D.
is primarily designed for healing wounds and ulcers using Manuka Honey (100%
Leptospermum scoparium Honey from New Zealand) in a e container, activated at
point-of-use with ascorbic acid (Vitamin C) and sodium bicarbonate powder to create an
expanding, pH adjusted (6.2), carbon dioxide (C02) infused, honey with Negative Osmotic
Pressure. The activated MANUKA N.O.P.D. is applied to a 4 in. X 4 in. foam pad dressing
(included), then secured in place with a suitable secondary ng or wrap.
Activated Manuka honey’s high sugar level provides Negative Osmotic Pressure
that promotes continuous autolytic debridement and helps maintain a moist environment
conducive to wound healing. Sodium bicarbonate rapidly absorbs and neutralizes wound
malodors. The C02 d consistency of the activated honey provides:
The benefits of this device include:
] 1) Improved ation and removal;
2) Expansion into undermined ortunneled areas of the wound without trauma or
discomfort to the patient; and
3) Temporary C02 rich atmosphere over the wound to discourages growth of
aerobic bacteria.
This medical device would n:
1) 0.502. (14g) sterile 100% Manuka (Leptospermum scoparium) Honey in a
flexible tube with foil seal under threaded cap;
2) Activator: 1.8g ascorbic acid and 0.6g sodium bicarbonate powder in sealed
container.
Example 7: Use of Manuka Honey Freeze Dried Granules Instead of Fluid
Honey in Wound Dressings
-dried Manuka Honey es were microencapsulated and blended with
ascorbic acid crystals (pH 3.6 - 4.5) in Cellulose Acetate Phthalate (CAP) and the
encapsulated mixture was adhered to the cellulose tissue layer of a gauze dressing. CAP is
typically used for pharmaceutical encapsulation to produce an enteric g that s
dissolution when in an acid environment, but dissolves when exposed to neutral to alkaline
solution.
Sodium bicarbonate was adhered to the outer rayon/polyester layer of the gauze
dressing. As wound fluid is absorbed by the dressing, the dissolving sodium bicarbonate
solution (pH 7-8) will cause dissolution of the CAP coating and reveal the honey and
ascorbic acid. The honey is extremely hygroscopic and will absorb and rehydrate with
wound fluid water to a honey tency (about 14% water). The honey organic acids and
ascorbic acid will react in the wound fluid water with dissolved sodium bicarbonate to e
carbon dioxide which infuses the now fluid honey to create the foam of this present patent
application.
Excess carbon dioxide is released from the non-occlusive gauze ng.
Occlusive adhesive border dressings should be avoided as they could inflate or even
dislodge with carbon dioxide pressure.
] Although the above mentioned tions of honey granules to ascorbic acid are
preferably suited for use in a wound healing ortreating formulation, a similar formulation can
be used forthe other uses mentioned in the t description. For example, in the case of
WO 74159
a debriding formulation, the amount of the sodium bicarbonate ent would be
preferably higher while the proportion of the ascorbic acid would be less.
References
1. Irish, J., Blair, 8., Carter D.A. “The Antibacterial Activity of Honey Derived
from Australian Flora.” PLoS ONE. 2011, 6(3): e18229.
] 2. Kwakman, P. H. S. et al. “Two Major Medicinal Honeys Have Different
Mechanisms of Bactericidal Activity.” PLoS ONE. 2011, 6(3): e17709.
3. Atrott, J., Henle, T. “Methylglyoxal in Manuka honey — ation with
antibacterial properties.” Czech Journal of Food Sciences. 2009, 27: 8163-8165.
4. Smith, A. M., Hunt, N.C., Shelton, R. M., Birdi, G., and Grover, L.M. “Alginate
Hydrogel Has a Negative Impact on In Vitro Collagen Deposition by Fibroblasts.”
Biomacromolecules. 2012, 13(12): 4032-4038.
5. Brandi, C. et al. “The Role of Carbon Dioxide Therapy in the Treatment of
Chronic Wounds”. In Vivo. 2010, 24: 223-226.
WHAT IS D IS:
1. A topical dressing sing at least a first layer and a second layer, wherein:
- the first layer comprises honey in a dry, granular form; and,
- the second layer comprises at least one pharmaceutically acceptable salt in a dry,
granular form, wherein the at least one salt is a carbonate (CO3-2) and/or bicarbonate (HCO3-
1) salt; and
- wherein at least one of the first and second layers further comprises at least one
organic acid in dry, granular form, wherein the organic acid is additional to the organic acids
naturally occurring in honey.
2. The dressing of claim 1, wherein the organic acid is provided in the first layer.
3. The dressing of claim 1 or 2, wherein the at least one organic acid is gluconic acid,
lactic acid, acetic acid, c acid, citric acid, malic acid, pyroglutamic acid, succinic acid,
ascorbic acid, glycolic acid, mandelic acid, or any combination thereof.
4. The dressing according to any one of claims 1 to 3, wherein the at least one organic
acid is ascorbic acid.
. The dressing of any one of claims 1 to 4, n the pharmaceutically acceptable
salt is sodium carbonate (Na2CO 3), potassium carbonate (K2CO 3), ammonium carbonate
((NH 4)2CO 3), sodium onate (NaHCO3), potassium bicarbonate (KHCO3), ammonium
bicarbonate ((NH4)HCO 3) or any combination thereof.
6. The dressing of any one of claims 1 to 4, wherein the pharmaceutically acceptable
salt is a bicarbonate salt.
7. The dressing of claim 6, wherein the ceutically acceptable salt is sodium
bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), ammonium bicarbonate
((NH 4)HCO 3) or any combination thereof.
8. The dressing of claim 6, wherein the pharmaceutically able salt is sodium
bicarbonate.
9. The dressing of any one of claims 1 to 8, wherein the honey granules are
ulated in a dissolvable coating.
. The dressing of any one of claims 1 to 9, wherein the honey es are adhered to
the first layer.
11. The dressing of any one of claims 1 to 10, wherein said honey is Manuka honey.
12. The dressing of any one of claims 1 to 11, wherein at least one of the first and
second layers further comprises at least one proteolytic enzyme, wherein the at least one
proteolytic enzyme is papain, actinidin, ain, ficain, cucumisin, a bacteria-derived
proteolytic enzyme, or any combination thereof.
13. The dressing of claim 12, wherein said proteolytic enzyme is actinidin.
14. The dressing of any one of claims 1 to 13, wherein at least one of the first and
second layers further comprises at least one preservative.
. The ng of claim 14, wherein the at least one preservative is methyl paraben,
propyl n, butyl paraben, imidazolidinyl urea, tetradecyl-trimethyl ammonium e
(Cetrimide®), sodium benzoate, potassium sorbate, thymol or polyaminopropyl biguanide, or
any combination thereof.
16. The dressing of any one of claims 1 to 15, wherein the dressing is adapted for use in
ghing, debriding, wound treating, exfoliating and/or cosmetic applications.
17. The dressing of claim 1, substantially as herein described with reference to any one
of the Examples and/or Figures thereof.
o Parcine D‘ebriding Efficiency
Dahfidem‘ent i—Haney finntml
*HaneyMousse 2.5%
anmga +Honey‘M DUSSE 5%
+HGRE§IMDLISSE 7.5%
+Hone’y‘M-Dusse 19%
*HaneyMDusse 12. 5%
i’reatmem fame
Figure 1
inVitro e Debriding Efficiency
Debridemem -E-Homsy Central
Marriage +Co§lagenase Ginxmum;
*Papain (Bintmem
*HoneyMaus-se i2.§%
24 Hrs 36 Hm ESQ Hrs
Treatmem mm
Figure 2
WO 74159
Day G {aftar 3% HIE}; wafih) [Jay ’7
Day BU Day 68
Figure 3
WO 74159
PCT CA2014/051124
Day 0 {aftm‘ al tic’bridement} Day 13
Day 32
Figure 5
WO 74159 PCT CA2014/051124
Claims (17)
1. A topical dressing sing at least a first layer and a second layer, wherein: - the first layer comprises honey in a dry, granular form; and, - the second layer comprises at least one pharmaceutically acceptable salt in a dry, granular form, wherein the at least one salt is a carbonate (CO3-2) and/or bicarbonate (HCO3- 1) salt; and - wherein at least one of the first and second layers further comprises at least one organic acid in dry, granular form, wherein the organic acid is additional to the organic acids naturally occurring in honey.
2. The dressing of claim 1, wherein the organic acid is provided in the first layer.
3. The dressing of claim 1 or 2, wherein the at least one organic acid is gluconic acid, lactic acid, acetic acid, c acid, citric acid, malic acid, pyroglutamic acid, succinic acid, ascorbic acid, glycolic acid, mandelic acid, or any combination thereof.
4. The dressing according to any one of claims 1 to 3, wherein the at least one organic acid is ascorbic acid.
5. The dressing of any one of claims 1 to 4, n the pharmaceutically acceptable salt is sodium carbonate (Na2CO 3), potassium carbonate (K2CO 3), ammonium carbonate ((NH 4)2CO 3), sodium onate (NaHCO3), potassium bicarbonate (KHCO3), ammonium bicarbonate ((NH4)HCO 3) or any combination thereof.
6. The dressing of any one of claims 1 to 4, wherein the pharmaceutically acceptable salt is a bicarbonate salt.
7. The dressing of claim 6, wherein the ceutically acceptable salt is sodium bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), ammonium bicarbonate ((NH 4)HCO 3) or any combination thereof.
8. The dressing of claim 6, wherein the pharmaceutically able salt is sodium bicarbonate.
9. The dressing of any one of claims 1 to 8, wherein the honey granules are ulated in a dissolvable coating.
10. The dressing of any one of claims 1 to 9, wherein the honey es are adhered to the first layer.
11. The dressing of any one of claims 1 to 10, wherein said honey is Manuka honey.
12. The dressing of any one of claims 1 to 11, wherein at least one of the first and second layers further comprises at least one proteolytic enzyme, wherein the at least one proteolytic enzyme is papain, actinidin, ain, ficain, cucumisin, a bacteria-derived proteolytic enzyme, or any combination thereof.
13. The dressing of claim 12, wherein said proteolytic enzyme is actinidin.
14. The dressing of any one of claims 1 to 13, wherein at least one of the first and second layers further comprises at least one preservative.
15. The ng of claim 14, wherein the at least one preservative is methyl paraben, propyl n, butyl paraben, imidazolidinyl urea, tetradecyl-trimethyl ammonium e (Cetrimide®), sodium benzoate, potassium sorbate, thymol or polyaminopropyl biguanide, or any combination thereof.
16. The dressing of any one of claims 1 to 15, wherein the dressing is adapted for use in ghing, debriding, wound treating, exfoliating and/or cosmetic applications.
17. The dressing of claim 1, substantially as herein described with reference to any one of the Examples and/or
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908611P | 2013-11-25 | 2013-11-25 | |
US61/908,611 | 2013-11-25 | ||
NZ721272A NZ721272B2 (en) | 2013-11-25 | 2014-11-25 | Composition, system and method for treating skin |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ759509A NZ759509A (en) | 2021-11-26 |
NZ759509B2 true NZ759509B2 (en) | 2022-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020201781B2 (en) | Composition, system and method for treating skin | |
JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
US9962402B2 (en) | Healing composition for topical application | |
WO2017011982A1 (en) | Mussel adhesive protein product and applications thereof in suppression of skin inflammations | |
Leon-Villapalos et al. | Topical management of facial burns | |
ES2526640T3 (en) | Compositions to break and inhibit the reconstitution of the wound biofilm | |
KR100673044B1 (en) | The composition for external use by percutaneous administration | |
WO2011119247A2 (en) | Topical skincare composition | |
CA2657718C (en) | Use of polyethylene glycol in inflammation related topical disorders or diseases and wound healing | |
WO1995016454A1 (en) | Method for treatment of papulo-pustules and comedones of the skin | |
NZ759509B2 (en) | Composition, system and method for treating skin | |
NZ721272B2 (en) | Composition, system and method for treating skin | |
US5616619A (en) | Topical composition for burn relief and method of use | |
Shirah et al. | Effect of surgical wound care methods of the lay open technique on the outcome of chronic sacrococcygeal pilonidal sinus management | |
US10071052B2 (en) | Method for the prevention and treatment of acne | |
RU2325900C2 (en) | Skin composition of external application | |
US20200138734A1 (en) | Topical formulation for treating bruising | |
US20200022935A1 (en) | Topical formulation for treating bruising | |
CN114732860A (en) | A compound medicinal composition for treating wound and scar, and its preparation method | |
DK177323B1 (en) | Compositions for wound healing of lying and pressure ulcers | |
US20100255070A1 (en) | Compositions and methods for preventing, minimizing and healing skin irritation and trauma | |
JPH08157386A (en) | Athlete's foot treating agent |